Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-Ku, Kitakyushu, Fukuoka, 802-8561, Japan.
Department of Pathology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-Ku, Kitakyushu, Fukuoka, 802-8561, Japan.
J Gastrointest Cancer. 2024 Oct 18;56(1):5. doi: 10.1007/s12029-024-01123-6.
Pancreatic adenosquamous carcinoma (PASC) is a subtype of pancreatic cancer with a poorer prognosis than pancreatic ductal carcinoma (PDAC). The pathogenesis of this histological subtype has not been fully explained due to its rarity.
Of the 245 patients who underwent pancreatic resection for pancreatic cancer, six (2.3%) were diagnosed with PASC. They were retrospectively allocated to Group A (≥ 50% adenocarcinoma components) or Group S (≥ 50% squamous cell carcinoma components).
The six patients with PASC were all males between the ages of 63 and 77 years, with tumors of 12 to 52 mm in diameter. Tumors were located in the pancreatic head (n = 2) and the pancreatic tail (n = 4). Relative to Group A, all three patients in Group S had larger tumors diameters, ≥ 40 mm with invasion to other organs. Cancer-specific survival of Group S was worse than that of the PDAC group (median survival, 1.5 years vs. 4.1 years). All patients in Group A were alive at the end of follow-up. Recurrence-free survival of Group S was inferior to that of the PDAC group (median survival, 0.2 years vs. 1.8 years; Group A, not defined). Immunohistochemistry revealed the MIB-1 positivity rate in squamous cell carcinoma regions was 1.8 times higher than that in adenocarcinoma regions in the same specimens.
In PASC patients, an increased proportion of squamous cell carcinoma components was associated with aggressive behavior and a worse prognosis. This was due to the high MIB-1 positivity rate of squamous cell carcinoma components.
胰腺腺鳞癌(PASC)是一种胰腺癌亚型,其预后比胰腺导管腺癌(PDAC)差。由于其罕见性,这种组织学亚型的发病机制尚未完全阐明。
在 245 例接受胰腺切除术治疗胰腺癌的患者中,有 6 例(2.3%)被诊断为 PASC。将其回顾性分配到 A 组(≥50%腺癌成分)或 S 组(≥50%鳞状细胞癌成分)。
6 例 PASC 患者均为 63-77 岁男性,肿瘤直径 12-52mm。肿瘤位于胰头部(n=2)和胰尾部(n=4)。与 A 组相比,S 组的所有 3 例患者肿瘤直径均较大,≥40mm 且侵犯其他器官。S 组的癌症特异性生存率低于 PDAC 组(中位生存时间,1.5 年比 4.1 年)。A 组所有患者在随访结束时均存活。S 组的无复发生存率低于 PDAC 组(中位生存时间,0.2 年比 1.8 年;A 组,未定义)。免疫组织化学显示,在同一标本中,鳞状细胞癌区域的 MIB-1 阳性率是腺癌区域的 1.8 倍。
在 PASC 患者中,鳞状细胞癌成分比例的增加与侵袭性行为和预后较差相关。这是由于鳞状细胞癌成分的高 MIB-1 阳性率所致。